Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 7.007
Filtrer
1.
Bull Exp Biol Med ; 177(4): 427-430, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39259465

RÉSUMÉ

We studied the effect of intramuscular injection of physostigmine and neostigmine on Na+,K+-ATPase activity in erythrocytes of rats subjected to intense physical exercise. Both anticholinesterase drugs had a significant effect on the development of the stress response, which was expressed in a decrease in the manifestation of its individual components such as the concentration of ascorbic acid in the adrenal glands, stress-related erythrocyte polycythemia, and LPO indicators. Anticholinesterase drugs reverse the stress-induced decrease in Na+,K+-ATPase activity, as well as changes in its magnesium-dependent properties. There were no changes in the activity of the studied enzyme in the erythrocyte ghosts. We associate the observed differences with the correction of the functions of the cholinergic components of the hypothalamic-pituitary-adrenal axis leading to the development of a hypoergic type stress reaction.


Sujet(s)
Anticholinestérasiques , Érythrocytes , Néostigmine , Conditionnement physique d'animal , Physostigmine , Rat Wistar , Sodium-Potassium-Exchanging ATPase , Animaux , Sodium-Potassium-Exchanging ATPase/métabolisme , Rats , Anticholinestérasiques/pharmacologie , Érythrocytes/effets des médicaments et des substances chimiques , Érythrocytes/enzymologie , Érythrocytes/métabolisme , Mâle , Physostigmine/pharmacologie , Néostigmine/pharmacologie , Stress physiologique/effets des médicaments et des substances chimiques , Acide ascorbique/pharmacologie , Peroxydation lipidique/effets des médicaments et des substances chimiques , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/métabolisme , Glandes surrénales/enzymologie , Membrane érythrocytaire/effets des médicaments et des substances chimiques , Membrane érythrocytaire/métabolisme
2.
Bull Exp Biol Med ; 177(4): 502-506, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39266917

RÉSUMÉ

A comparative analysis of morphological and functional changes in the adrenal glands after embolization of supplying arteries with Lifepearl microspheres (100±25 µm; Terumo) and with a solution of polidocanol (Aethoxysklerol, Kreussler Pharma) was performed in male Vietnamese Lop-Bellied pigs (n=20). The introduction of the microspheres into the arterial bed did not affect the adrenal parenchyma. However, the injection of the liquid sclerosing agent caused foci of productive inflammation leading to the formation of sclerotic tissue and reduction of the volume of glandular tissue. Administration of the sclerosant was accompanied by arterial hypotension, an indirect indication of a decrease in vasoactive hormone production by the adrenal cortex. These findings suggest that polidocanol can be used as an embolization agent for hyperplastic diseases of the adrenal cortex.


Sujet(s)
Glandes surrénales , Embolisation thérapeutique , Animaux , Mâle , Suidae , Glandes surrénales/effets des médicaments et des substances chimiques , Embolisation thérapeutique/méthodes , Polidocanol/pharmacologie , Microsphères , Solutions sclérosantes/usage thérapeutique , Solutions sclérosantes/pharmacologie , Cortex surrénal/effets des médicaments et des substances chimiques , Cortex surrénal/métabolisme
3.
Crit Care ; 28(1): 295, 2024 Sep 05.
Article de Anglais | MEDLINE | ID: mdl-39238038

RÉSUMÉ

BACKGROUND: Hypocholesterolemia hallmarks critical illness though the underlying pathophysiology is incompletely understood. As low circulating cholesterol levels could partly be due to an increased conversion to cortisol/corticosterone, we hypothesized that glucocorticoid treatment, via reduced de novo adrenal cortisol/corticosterone synthesis, might improve cholesterol availability and as such affect adrenal gland and skeletal muscle function. METHODS: In a matched set of prolonged critically ill patients (n = 324) included in the EPaNIC RCT, a secondary analysis was performed to assess the association between glucocorticoid treatment and plasma cholesterol from ICU admission to day five. Next, in a mouse model of cecal ligation and puncture-induced sepsis, septic mice were randomized to receive either hydrocortisone (1.2 mg/day) (n = 17) or placebo (n = 15) for 5 days, as compared with healthy mice (n = 18). Plasma corticosterone, cholesterol, and adrenocortical and myofiber cholesterol were quantified. Adrenal structure and steroidogenic capacity were evaluated. Muscle force and markers of atrophy, fibrosis and regeneration were quantified. In a consecutive mouse study with identical design (n = 24), whole body composition was assessed by EchoMRI to investigate impact on lean mass, fat mass, total and free water. RESULTS: In human patients, glucocorticoid treatment was associated with higher plasma HDL- and LDL-cholesterol from respectively ICU day two and day three, up to day five (P < 0.05). Plasma corticosterone was no longer elevated in hydrocortisone-treated septic mice compared to placebo, whereas the sepsis-induced reduction in plasma HDL- and LDL-cholesterol and in adrenocortical cholesterol was attenuated (P < 0.05), but without improving the adrenocortical ACTH-induced CORT response and with increased adrenocortical inflammation and apoptosis (P < 0.05). Total body mass was further decreased in hydrocortisone-treated septic mice (P < 0.01) compared to placebo, with no additional effect on muscle mass, force or myofiber size. The sepsis-induced rise in markers of muscle atrophy and fibrosis was unaffected by hydrocortisone treatment, whereas markers of muscle regeneration were suppressed compared to placebo (P < 0.05). An increased loss of lean body mass and total and free water was observed in hydrocortisone-treated septic mice compared to placebo (P < 0.05). CONCLUSIONS: Glucocorticoid treatment partially attenuated critical illness-induced hypocholesterolemia, but at a cost of impaired adrenal function, suppressed muscle regeneration and exacerbated loss of body mass.


Sujet(s)
Glandes surrénales , Cholestérol , Maladie grave , Glucocorticoïdes , Muscles squelettiques , Animaux , Maladie grave/thérapie , Humains , Souris , Glucocorticoïdes/usage thérapeutique , Glucocorticoïdes/pharmacologie , Cholestérol/sang , Cholestérol/analyse , Mâle , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/physiopathologie , Adulte d'âge moyen , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/physiopathologie , Femelle , Sujet âgé , Hydrocortisone/analyse , Hydrocortisone/usage thérapeutique , Hydrocortisone/sang , Sepsie/traitement médicamenteux , Sepsie/physiopathologie , Sepsie/complications , Modèles animaux de maladie humaine
4.
Bull Exp Biol Med ; 177(3): 301-306, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-39126542

RÉSUMÉ

We studied the effect of enteral administration of GABA on the gastric mucosa in male Wistar rats (n=47) with modeled metabolic stress (food deprivation for 9 days with free access to water). The relative weights of the adrenal glands and thymus were determined, and histological examination of the stomach was performed. In control rats, modeling the metabolic stress was accompanied by the development of erosive damage to the gastric mucosa related to blood supply disturbances. Administration of GABA prevented erosions and exhibited a pronounced gastroprotective effect. Thus, administration of GABA can be a promising method for the prevention and treatment of erosive gastric lesions associated with metabolic stress.


Sujet(s)
Muqueuse gastrique , Rat Wistar , Stress physiologique , Acide gamma-amino-butyrique , Animaux , Mâle , Acide gamma-amino-butyrique/métabolisme , Acide gamma-amino-butyrique/pharmacologie , Rats , Muqueuse gastrique/effets des médicaments et des substances chimiques , Muqueuse gastrique/métabolisme , Muqueuse gastrique/anatomopathologie , Stress physiologique/effets des médicaments et des substances chimiques , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/métabolisme , Glandes surrénales/anatomopathologie , Thymus (glande)/effets des médicaments et des substances chimiques , Thymus (glande)/anatomopathologie , Thymus (glande)/métabolisme , Privation alimentaire , Ulcère gastrique/métabolisme , Ulcère gastrique/anatomopathologie , Ulcère gastrique/prévention et contrôle , Ulcère gastrique/induit chimiquement , Ulcère gastrique/traitement médicamenteux
5.
Mol Nutr Food Res ; 68(18): e2400323, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39148153

RÉSUMÉ

SCOPE: The aim of this study is to investigate the effect of time-of-day on serum hormones and gene expression in adrenal glands, studying the impact of sex, obesogenic diet, and timing of proanthocyanidins administration, with a focus on glucocorticoids synthesis by this gland. METHODS AND RESULTS: Female and male rats, assigned to a standard chow or a cafeteria diet-fed group, receive a daily oral dose of a grape seed proanthocyanidin extract (GSPE), or a vehicle (when light is turned on, or when light is turned off). Corticosterone, estradiol, and testosterone serum levels, and the expression analysis of clock genes and genes related to corticosterone synthesis pathway, are assessed. Serum hormone levels exhibited a marked time-of-day effect also see in the expression of scavenger receptor class B member 1 (Scarb1) and cyp11b genes. The correlation between these two genes and period circadian regulator 2 (Per2) is also extended to other clock genes, although to a lesser extent: cryptochrome (Cry) and nuclear receptor subfamily 1 group D member 1 (Rev-erba). CONCLUSION: The strong correlations found suggest an important role of local Per2 (but also of Cry and Rev-erbA) in regulating the expression of the enzymes involved in the corticosterone synthesis pathway. The expression of clock genes in adrenals is influenced by sex and diet but not by GSPE.


Sujet(s)
Glandes surrénales , Corticostérone , Extrait de pépins de raisin , Proanthocyanidines , Testostérone , Animaux , Corticostérone/sang , Mâle , Proanthocyanidines/pharmacologie , Femelle , Glandes surrénales/métabolisme , Glandes surrénales/effets des médicaments et des substances chimiques , Extrait de pépins de raisin/pharmacologie , Testostérone/sang , Oestradiol/sang , Récepteurs éboueurs de classe B/génétique , Récepteurs éboueurs de classe B/métabolisme , Rat Wistar , Régime alimentaire/méthodes , Steroid 11-beta-hydroxylase/génétique , Steroid 11-beta-hydroxylase/métabolisme , Protéines circadiennes Period/génétique , Protéines circadiennes Period/métabolisme , Rats , Cryptochromes/génétique , Cryptochromes/métabolisme
6.
Sci Rep ; 14(1): 17481, 2024 07 30.
Article de Anglais | MEDLINE | ID: mdl-39080323

RÉSUMÉ

Carbimazole has disadvantages on different body organs, especially the thyroid gland and, rarely, the adrenal glands. Most studies have not suggested any solution or medication for ameliorating the noxious effects of drugs on the glands. Our study focused on the production of xylooligosaccharide (XOS), which, when coadministered with carbimazole, relieves the toxic effects of the drug on the adrenal glands. In addition to accelerating the regeneration of adrenal gland cells, XOS significantly decreases the oxidative stress caused by obesity. This XOS produced by Aspergillus terreus xylanase was covalently immobilized using microbial Scleroglucan gel beads, which improved the immobilization yield, efficiency, and operational stability. Over a wide pH range (6-7.5), the covalent immobilization of xylanase on scleroglucan increased xylanase activity compared to that of its free form. Additionally, the reaction temperature was increased to 65 °C. However, the immobilized enzyme demonstrated superior thermal stability, sustaining 80.22% of its original activity at 60 °C for 120 min. Additionally, the full activity of the immobilized enzyme was sustained after 12 consecutive cycles, and the activity reached 78.33% after 18 cycles. After 41 days of storage at 4 °C, the immobilized enzyme was still active at approximately 98%. The immobilized enzyme has the capability to produce xylo-oligosaccharides (XOSs). Subsequently, these XOSs can be coadministered alongside carbimazole to mitigate the adverse effects of the drug on the adrenal glands. In addition to accelerating the regeneration of adrenal gland cells, XOS significantly decreases the oxidative stress caused by obesity.


Sujet(s)
Glandes surrénales , Aspergillus , Carbimazole , Enzymes immobilisées , Oligosaccharides , Aspergillus/effets des médicaments et des substances chimiques , Oligosaccharides/pharmacologie , Oligosaccharides/composition chimique , Enzymes immobilisées/métabolisme , Enzymes immobilisées/composition chimique , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/métabolisme , Animaux , Glucuronates/pharmacologie , Stress oxydatif/effets des médicaments et des substances chimiques , Endo-1,4-beta xylanases/métabolisme , Mâle , Rats , Obésité/traitement médicamenteux
7.
Tuberculosis (Edinb) ; 148: 102548, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39068772

RÉSUMÉ

Research suggests that both tuberculosis (TB) and type 2 diabetes mellitus (T2DM) have an immuno-endocrine imbalance characterized by dysregulated proinflammatory molecules and hormone levels (high cortisol/DHEA ratio), impeding an effective immune response against Mycobacterium tuberculosis (Mtb) driven by cytokines, antimicrobial peptides (AMPs), and androgens like DHEA. Insulin, sulfonylurea derivatives, and metformin are commonly used glucose-lowering drugs in patients suffering from TB and T2DM. For this comorbidity, metformin is an attractive target to restore the immunoendocrine mechanisms dysregulated against Mtb. This study aimed to assess whether metformin influences cortisol and DHEA synthesis in adrenal cells and if these hormones influence the expression of proinflammatory cytokines and AMPs in Mtb-infected macrophages. Our results suggest that metformin may enhance DHEA synthesis while maintaining cortisol homeostasis. In addition, supernatants from metformin-treated adrenal cells decreased mycobacterial loads in macrophages, which related to rising proinflammatory cytokines and AMP expression (HBD-2 and 3). Intriguingly, we find that HBD-3 and LL-37 can modulate steroid synthesis in adrenal cells with diminished levels of cortisol and DHEA, highlighting the importance of crosstalk communication between adrenal hormones and these effectors of innate immunity. We suggest that metformin's effects can promote innate immunity against Mtb straight or through modulation of corticosteroid hormones.


Sujet(s)
Cytokines , Déhydroépiandrostérone , Hydrocortisone , Macrophages , Metformine , Mycobacterium tuberculosis , Metformine/pharmacologie , Humains , Macrophages/métabolisme , Macrophages/effets des médicaments et des substances chimiques , Macrophages/microbiologie , Macrophages/immunologie , Mycobacterium tuberculosis/effets des médicaments et des substances chimiques , Hydrocortisone/métabolisme , Déhydroépiandrostérone/pharmacologie , Cytokines/métabolisme , Immunité innée/effets des médicaments et des substances chimiques , Cellules THP-1 , Interactions hôte-pathogène , Cellules cultivées , Hypoglycémiants/pharmacologie , Glandes surrénales/métabolisme , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/microbiologie , Médiateurs de l'inflammation/métabolisme
8.
Metabolism ; 160: 155980, 2024 Nov.
Article de Anglais | MEDLINE | ID: mdl-39053691

RÉSUMÉ

BACKGROUND: The effect of coronavirus disease 2019 (COVID-19) on adrenal endocrine metabolism in critically ill patients remains unclear. This study aimed to investigate the alterations in adrenal steroidogenic activity, elucidate underlying mechanisms, provide in situ histopathological evidence, and examine the clinical implications. METHODS: The comparative analyses of the adrenal cortices from 24 patients with fatal COVID-19 and 20 matched controls were performed, excluding patients previously treated with glucocorticoids. SARS-CoV-2 and its receptors were identified and pathological alterations were examined. Furthermore, histological examinations, immunohistochemical staining and ultrastructural analyses were performed to assess corticosteroid biosynthesis. The zona glomerulosa (ZG) and zona fasciculata (ZF) were then dissected for proteomic analyses. The biological processes that affected steroidogenesis were analyzed by integrating histological, proteomic, and clinical data. Finally, the immunoreactivity and responsive genes of mineralocorticoid and glucocorticoid receptors in essential tissues were quantitatively measured to evaluate corticosteroid responsiveness. FINDINGS: The demographic characteristics of COVID-19 patients were comparable with those of controls. SARS-CoV-2-like particles were identified in the adrenocortical cells of three patients; however, these particles did not affect cellular morphology or steroid synthesis compared with SARS-CoV-2-negative specimens. Although the adrenals exhibited focal necrosis, vacuolization, microthrombi, and inflammation, widespread degeneration was not evident. Notably, corticosteroid biosynthesis was significantly enhanced in both the ZG and ZF of COVID-19 patients. The increase in the inflammatory response and cellular differentiation in the adrenal cortices of patients with critical COVID-19 was positively correlated with heightened steroidogenic activity. Additionally, the appearance of more dual-ZG/ZF identity cells in COVID-19 adrenals was in accordance with the increased steroidogenic function. However, activated mineralocorticoid and glucocorticoid receptors and their responsive genes in vital tissues were markedly reduced in patients with critical COVID-19. INTERPRETATION: Critical COVID-19 was characterized by potentiated adrenal steroidogenesis, associated with increased inflammation, enhanced differentiation and elevated dual-ZG/ZF identity cells, alongside suppressed corticosteroid responsiveness. These alterations implied the reduced effectiveness of conventional corticosteroid therapy and underscored the need for evaluation of the adrenal axis and corticosteroid sensitivity.


Sujet(s)
Hormones corticosurrénaliennes , COVID-19 , Maladie grave , Humains , COVID-19/métabolisme , Mâle , Femelle , Adulte d'âge moyen , Hormones corticosurrénaliennes/usage thérapeutique , Hormones corticosurrénaliennes/biosynthèse , Sujet âgé , SARS-CoV-2 , Zone fasciculée/métabolisme , Zone fasciculée/effets des médicaments et des substances chimiques , Récepteurs aux glucocorticoïdes/métabolisme , Adulte , Cortex surrénal/métabolisme , Cortex surrénal/effets des médicaments et des substances chimiques , Cortex surrénal/anatomopathologie , Zone glomérulée/métabolisme , Zone glomérulée/effets des médicaments et des substances chimiques , Zone glomérulée/anatomopathologie , Glandes surrénales/métabolisme , Glandes surrénales/effets des médicaments et des substances chimiques
9.
Immun Inflamm Dis ; 12(7): e1315, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-39031511

RÉSUMÉ

BACKGROUND: Asthma is routinely treated with inhaled corticosteroids (ICS). Asthma patients on ICS are at increased risk of adrenal suppression, a potentially serious effect of long-term glucocorticoid exposure; however, this relationship is poorly understood. Therefore, this study aims to identify metabolite biomarkers related to adrenal suppression in asthma patients taking ICS. METHODS: A total of 571 urine metabolites from 200 children with asthma on ICS in the Pharmacogenetics of Adrenal Suppression with Inhaled Steroids (PASS) cohort were profiled. Samples were grouped by peak plasma cortisol measurement as adrenal sufficient (>350 nmol/L) or insufficient (≤350 nmol/L) (outcome). Regression and discriminant-based statistical models combined with network analyses were utilized to assess relationships between metabolites and the outcome. Finally, prioritized metabolites were validated using data from an ancillary study of the Childhood Asthma Management (CAMP) cohort with similar characteristics to PASS. RESULTS: Ninety metabolites were significantly associated with adrenal suppression, of which 57 also could discriminate adrenal status. While 26 metabolites (primarily steroids) were present at lower levels in the adrenal insufficient patients, 14 were significantly elevated in this group; the top metabolite, mannitol/sorbitol, was previously associated with asthma exacerbations. Network analyses identified unique clusters of metabolites related to steroids, fatty acid oxidation, and nucleoside metabolism, respectively. Four metabolites including urocanic acid, acetylcarnitine, uracil, and sorbitol were validated in CAMP cohort for adrenal suppression. CONCLUSIONS: Urinary metabolites differ among asthma patients on ICS, by adrenal status. While steroid metabolites were reduced in patients with poor adrenal function, our findings also implicate previously unreported metabolites involved in amino acid, lipid, and nucleoside metabolism.


Sujet(s)
Hormones corticosurrénaliennes , Asthme , Métabolomique , Humains , Asthme/traitement médicamenteux , Asthme/urine , Asthme/sang , Asthme/diagnostic , Enfant , Mâle , Femelle , Administration par inhalation , Métabolomique/méthodes , Hormones corticosurrénaliennes/administration et posologie , Hormones corticosurrénaliennes/usage thérapeutique , Marqueurs biologiques/urine , Marqueurs biologiques/sang , Adolescent , Métabolome/effets des médicaments et des substances chimiques , Insuffisance surrénale/diagnostic , Insuffisance surrénale/sang , Insuffisance surrénale/urine , Insuffisance surrénale/étiologie , Insuffisance surrénale/traitement médicamenteux , Enfant d'âge préscolaire , Hydrocortisone/sang , Hydrocortisone/urine , Glandes surrénales/métabolisme , Glandes surrénales/effets des médicaments et des substances chimiques , Études de cohortes
10.
Sci Rep ; 14(1): 13209, 2024 06 08.
Article de Anglais | MEDLINE | ID: mdl-38851835

RÉSUMÉ

Hypertension remains a leading cause of cardiovascular and kidney diseases. Failure to control blood pressure with ≥ 3 medications or control requiring ≥ 4 medications is classified as resistant hypertension (rHTN) and new therapies are needed to reduce the resulting increased risk of morbidity and mortality. Here, we report genetic evidence that relaxin family peptide receptor 2 (RXFP2) is associated with rHTN in men, but not in women. This study shows that adrenal gland gene expression of RXFP2 is increased in men with hypertension and the RXFP2 natural ligand, INSL3, increases adrenal steroidogenesis and corticosteroid secretion in human adrenal cells. To address the hypothesis that RXFP2 activation is an important mechanism in rHTN, we discovered and characterized small molecule and monoclonal antibody (mAb) blockers of RXFP2. The novel chemical entities and mAbs show potent, selective inhibition of RXFP2 and reduce aldosterone and cortisol synthesis and release. The RXFP2 mAbs have suitable rat pharmacokinetic profiles to evaluate the role of RXFP2 in the development and maintenance of rHTN. Overall, we identified RXFP2 activity as a potential new mechanism in rHTN and discovered RXFP2 antagonists for the future interrogation of RXFP2 in cardiovascular and renal diseases.


Sujet(s)
Hypertension artérielle , Récepteurs couplés aux protéines G , Récepteurs peptidiques , Humains , Mâle , Hypertension artérielle/traitement médicamenteux , Hypertension artérielle/génétique , Récepteurs couplés aux protéines G/antagonistes et inhibiteurs , Récepteurs couplés aux protéines G/génétique , Récepteurs couplés aux protéines G/métabolisme , Animaux , Récepteurs peptidiques/génétique , Récepteurs peptidiques/métabolisme , Récepteurs peptidiques/antagonistes et inhibiteurs , Rats , Femelle , Anticorps monoclonaux/pharmacologie , Anticorps monoclonaux/usage thérapeutique , Glandes surrénales/métabolisme , Glandes surrénales/effets des médicaments et des substances chimiques , Résistance aux substances/génétique , Antihypertenseurs/pharmacologie , Aldostérone/métabolisme
13.
Mol Pharm ; 21(5): 2435-2440, 2024 May 06.
Article de Anglais | MEDLINE | ID: mdl-38626389

RÉSUMÉ

Among clinically used radiopharmaceuticals, iodine-123 labeled metaiodobenzylguanidine ([123I]mIBG) serves for diagnosing neuroendocrine tumors and obtaining images of myocardial sympathetic innervation. mIBG, a structural analogue of norepinephrine (NE), a neurotransmitter acting in peripheral and central nerves, follows a pathway similar to NE, transmitting signals through the NE transporter (NET) located at synaptic terminals. It moves through the body without decomposing, enabling noninvasive image evaluation. In this study, we aimed to quantify [123I]mIBG uptake in the adrenal glands using small animal single-photon emission computed tomography/computed tomography (SPECT/CT) images post [123I]mIBG administration. We investigated the possibility of assessing the effectiveness of ß-adrenergic receptor blockers by quantifying SPECT/CT images and biodistribution results to determine the degree of [123I]mIBG uptake in the adrenal glands treated with labetalol, a known ß-adrenergic receptor blocker. Upon intravenous administration of [123I]mIBG to mice, SPECT/CT images were acquired over time to confirm the in vivo distribution pattern, revealing a clear uptake in the adrenal glands. Labetalol inhibited the uptake of [123I]mIBG in cell lines expressing NET. A decrease in [123I]mIBG uptake in the adrenal glands was observed in the labetalol-treated group compared with the normal group through SPECT/CT imaging and biodistribution studies. These results demonstrate that SPECT/CT imaging with [123I]mIBG could be applicable for evaluating the preclinical efficacy of new antihypertensive drug candidates such as labetalol, a ß-adrenergic receptor blocker.


Sujet(s)
3-Iodobenzyl-guanidine , Antagonistes bêta-adrénergiques , Radio-isotopes de l'iode , Labétalol , Animaux , Humains , Mâle , Souris , Glandes surrénales/imagerie diagnostique , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/métabolisme , Antagonistes bêta-adrénergiques/pharmacologie , Antagonistes bêta-adrénergiques/pharmacocinétique , Lignée cellulaire tumorale , Études de faisabilité , Transporteurs de la norépinéphrine/métabolisme , Transporteurs de la norépinéphrine/antagonistes et inhibiteurs , Radiopharmaceutiques/pharmacocinétique , Tomographie par émission monophotonique couplée à la tomodensitométrie , Distribution tissulaire
14.
Poult Sci ; 103(6): 103712, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38603935

RÉSUMÉ

The effects of the administration of the opioid agonist, morphine, on plasma and tissue concentrations of Met-enkephalin were determined in 14 wk old female chickens. In addition, effects of morphine on proenkephalin (PENK) expression were examined. Plasma concentrations of Met-enkephalin were reduced 10 minutes after morphine administration. Plasma concentrations of peptides that contain Met-enkephalin motifs were decreased 30 minutes after morphine administration. Tissue concentrations of Met-enkephalin tended to be depressed following morphine administration. Adrenal concentrations of PENK peptides containing Met-enkephalin motifs were decreased in chickens challenged with morphine. Expression of PENK in the anterior pituitary gland and adrenal glands were decreased in morphine treated compared to control pullets. In contrast, plasma concentrations of corticosterone were elevated 10 min after morphine treatment. Morphine also induced changes in mu (µ) opioid receptors and delta (δ) opioid receptors in both anterior pituitary tissue and adrenal tissues.


Sujet(s)
Poulets , Corticostérone , Méthionine-enképhaline , Enképhalines , Morphine , Précurseurs de protéines , Animaux , Morphine/administration et posologie , Morphine/pharmacologie , Poulets/métabolisme , Méthionine-enképhaline/métabolisme , Femelle , Corticostérone/sang , Précurseurs de protéines/métabolisme , Enképhalines/métabolisme , Analgésiques morphiniques/administration et posologie , Analgésiques morphiniques/pharmacologie , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/métabolisme , Protéines aviaires/métabolisme , Protéines aviaires/génétique
15.
Auton Neurosci ; 248: 103105, 2023 09.
Article de Anglais | MEDLINE | ID: mdl-37393658

RÉSUMÉ

BACKGROUND: Many patients with postural orthostatic tachycardia syndrome (POTS) are hypovolemic with plasma volume deficits of 10-30 %. Some also have low levels of aldosterone and diminished aldosterone-renin ratios despite elevations in angiotensin II, pointing to potential adrenal dysfunction. To assess adrenal gland responsiveness in POTS, we measured circulating levels of aldosterone and cortisol following adrenocorticotropin hormone (ACTH) stimulation. METHODS: While on a low Na+ diet (∼10 mEq/day), 8 female patients with POTS and 5 female healthy controls (HC) received a low dose (1 µg) ACTH bolus following a baseline blood sample. After 60 min, a high dose (249 µg) infusion of ACTH was administered to ensure maximal adrenal response. Venous aldosterone and cortisol levels were sampled every 30 min for 2 h. RESULTS: Aldosterone increased in both groups in response to ACTH but was not different between POTS vs. HC at 60 min (53.5 ng/dL [37.8-61.8 ng/dL] vs. 46.1 ng/dL [36.7-84.9 ng/dL]; P = 1.000) or maximally (56.4 ng/dL [49.2-67.1 ng/dL] vs. 49.5 ng/dL [39.1-82.8 ng/dL]; P = 0.524). Cortisol increased in both groups in response to ACTH but was not different in patients with POTS vs. HC at 60 min (39.9 µg/dL [36.1-47.7 µg/dL] vs. 39.3 µg/dL [35.4-46.6 µg/dL]; P = 0.724) or maximally (39.9 µg/dL [33.9-45.4 µg/dL] vs. 42.0 µg/dL [37.6-49.7 µg/dL]; P = 0.354). CONCLUSIONS: ACTH appropriately increased the aldosterone and cortisol levels in patients with POTS. These findings suggest that the response of the adrenal cortex to hormonal stimulation is intact in patients with POTS.


Sujet(s)
Glandes surrénales , Hormone corticotrope , Syndrome de tachycardie orthostatique posturale , Glandes surrénales/effets des médicaments et des substances chimiques , Humains , Hormone corticotrope/administration et posologie , Hormone corticotrope/pharmacologie , Syndrome de tachycardie orthostatique posturale/traitement médicamenteux , Aldostérone/sang , Études cas-témoins , Hypovolémie , Hydrocortisone/sang , Mâle , Femelle , Adulte , Adulte d'âge moyen
16.
Drug Chem Toxicol ; 46(3): 482-490, 2023 May.
Article de Anglais | MEDLINE | ID: mdl-35361025

RÉSUMÉ

N-acetyl cysteine (NAC) is a nutritional supplement and greatly applied as an antioxidant in vivo and in vitro. Therefore, this study aimed to assess the metabolic and antioxidant protective effect of NAC against selenium (Se) toxicity and gamma irradiation in rats by measuring biochemical and molecular parameters. This study was conducted on sixty rats divided into six equal different groups; control, NAC, Rad, Se, Rad + NAC, and Se + NAC groups. Oxidative/nitrosative makers (LPO, NO, and NOS), antioxidants status markers (GSH, GPx, and SOD), liver metabolic markers (LDH, SDH, and ATP), and plasma metabolic markers (Glucose, total cholesterol, and total proteins) were measured using commercial colorimetric kits while plasma corticosterone concentration was measured using commercial ELISA kit. Also, Levels of NR3C1 and Glut-2 genes expression using reverse transcription-quantitative polymerase chain reaction were done. Our results revealed that Se toxicity and gamma irradiation induced significant increases in oxidative/nitrosative stress markers and a significant decrease in antioxidant status markers in the liver and adrenal tissues. Moreover, metabolic disorders were recorded as manifested by elevation of plasma ALT, Albumin, glucose and cholesterol, and decrease in protein levels associated with a significant increase in corticosterone concentration. This was also accompanied by a significant decrease in SDH activity and ATP production in the hepatic tissue. Molecular analysis showed a marked increase in NR3C1 mRNA and decrease in Glut-2 mRNA in liver tissue. However, NAC supplementation attenuated the changes induced by these toxins. Finally, we could conclude that, oral supplementation of NAC can modulate the metabolic disturbances and has protective effects in rats exposed to Se toxicity and gamma irradiation.


Sujet(s)
Acétylcystéine , Antioxydants , Rayons gamma , Foie , Sélénium , Animaux , Rats , Acétylcystéine/métabolisme , Acétylcystéine/pharmacologie , Adénosine triphosphate/métabolisme , Antioxydants/pharmacologie , Antioxydants/métabolisme , Cholestérol/métabolisme , Cholestérol/pharmacologie , Corticostérone/métabolisme , Corticostérone/pharmacologie , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Foie/effets des radiations , Stress oxydatif , Sélénium/toxicité , Rayons gamma/effets indésirables , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/métabolisme , Glandes surrénales/effets des radiations
17.
Environ Toxicol Pharmacol ; 89: 103780, 2022 Jan.
Article de Anglais | MEDLINE | ID: mdl-34864161

RÉSUMÉ

Phthalate esters such as di-butyl phthalate (DBP) and di-ethyl hexyl phthalate (DEHP) used in personal care and consumer products and medical devices have potential to affect human health. We studied the effect of DBP and DEHP on critical enzymes of glucocorticoid biosynthesis pathway in the adrenal gland and pro-inflammatory cytokines in the serum in male Wistar rats. DEHP and DBP treatment altered the mRNA expression of enzymes of glucocorticoid biosynthesis pathway accompanied by a reduction in glucocorticoid production and elevation in the level of glucocorticoid regulated pro-inflammatory cytokines indicating a cascading effect of phthalates. The analysis of PPI (protein - protein interaction) network involving Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) of enzymes through STRING database revealed that all the proteins have the maximum level of interaction with the selected number of proteins. The STRING database analysis together with in vivo data indicates the potential effects of phthalates on various targets of steroidogenesis pathway with a global biological impact.


Sujet(s)
Phtalate de dibutyle/toxicité , Phtalate de bis[2-éthylhexyle]/toxicité , Cartes d'interactions protéiques , ARN messager/métabolisme , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/métabolisme , Animaux , Cytokines , Glucocorticoïdes/biosynthèse , Inflammation , Mâle , Plastifiants/toxicité , ARN messager/génétique , Rat Wistar
18.
J Clin Endocrinol Metab ; 107(2): e538-e547, 2022 01 18.
Article de Anglais | MEDLINE | ID: mdl-34558612

RÉSUMÉ

CONTEXT: An institutional study previously demonstrated that cosyntropin stimulation testing on postoperative day 1 (POD1-CST) identified patients at risk for adrenal insufficiency (AI) following unilateral adrenalectomy (UA) for adrenal-dependent hypercortisolism (HC) and primary aldosteronism (PA), allowing for selective glucocorticoid replacement (GR). OBJECTIVE: This study re-evaluates the need for GR following UA for patients with HC and PA in a larger cohort. METHODS: A prospective database identified 108 patients who underwent UA for mild autonomous cortisol excess (MACE) (n = 47), overt hypercortisolism (OH) (n = 27), PA (n = 22), and concurrent PA/HC (n = 12) from September 2014 to October 2020; all underwent preoperative evaluation for HC. MACE was defined by the 1 mg dexamethasone suppression test (cortisol >1.8 µg/dL), with ≥5 defined as OH. GR was initiated for basal cortisol ≤5 or stimulated cortisol ≤14 (≤18 prior to April 2017) on POD1-CST. RESULTS: Fifty-one (47%) patients had an abnormal POD1-CST; 54 (50%) were discharged on GR (27 MACE, 20 OH, 1 PA, 6 PA/HC). Median duration of GR was OH: 6.0 months, MACE: 2.1 months, PA: 1 month, PA/HC: 0.8 months. Overall, 26% (n = 7) of patients with OH and 43% (n = 20) of patients with MACE did not require GR. Two (2%) patients with OH had normal POD1-CST but developed AI several weeks postoperatively requiring GR. None experienced life-threatening AI. CONCLUSION: POD1-CST identifies patients with HC at risk for AI after UA, allowing for selective GR. One-quarter of patients with OH and nearly half of patients with MACE can forgo GR after UA. Patients with PA do not require evaluation for AI if concurrent HC has been excluded preoperatively.


Sujet(s)
Insuffisance surrénale/épidémiologie , Surrénalectomie/effets indésirables , Syndrome de Cushing/chirurgie , Hormonothérapie substitutive/statistiques et données numériques , Hyperaldostéronisme/chirurgie , Complications postopératoires/épidémiologie , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/métabolisme , Glandes surrénales/chirurgie , Insuffisance surrénale/traitement médicamenteux , Insuffisance surrénale/étiologie , Sujet âgé , Tétracosactide/administration et posologie , Femelle , Glucocorticoïdes/administration et posologie , Glucocorticoïdes/sang , Glucocorticoïdes/métabolisme , Hormonothérapie substitutive/méthodes , Humains , Mâle , Adulte d'âge moyen , Complications postopératoires/traitement médicamenteux , Complications postopératoires/étiologie , Période postopératoire , Études prospectives , Études rétrospectives , Appréciation des risques/méthodes
19.
Front Endocrinol (Lausanne) ; 12: 784706, 2021.
Article de Anglais | MEDLINE | ID: mdl-34899614

RÉSUMÉ

Background: Adrenocorticotropic hormone (ACTH) is widely used in adrenal vein sampling (AVS) and can be administered as a bolus injection or continuous infusion. The optimal administration method has not been determined. We aimed to compare the effects of ACTH bolus with infusion on cannulation success, lateralization assessment and adverse events (AEs). Methods: Retrospectively collected data from patients with primary aldosteronism who underwent AVS with ACTH at a tertiary hospital in China. Rate of successful cannulation, lateralization index (LI), complete biochemical remission and AEs related to AVS were analyzed. Results: The study included 80 patients receiving ACTH bolus and 94 receiving infusions. The rate of successful cannulation was comparable between bolus and infusion groups (75/80, 93.4% vs 88/94, 93.6%). In those with successful cannulation, the bolus group had a higher selectivity index than the infusion group, while LI [6.4(1.8-17.5) vs. 7.6(2.0-27.8), P=0.48] and rate of complete biochemical remission (43/44, 97.7% vs 53/53, 100%, P=0.45) did not significantly differ between the two groups. One in the bolus and one patient in the infusion group had adrenal vein rupture but they recovered with conservative treatment. The bolus group reported more transient AEs such as palpitation (52.9% vs 2.2%) and abdominal discomfort (40.0% vs 2.2%) than the infusion group. Conclusions: Due to their similar effects on cannulation success and lateralization, but a lower rate of transient AEs in the infusion group, the continuous infusion method should be recommended for ACTH stimulation in AVS.


Sujet(s)
Glandes surrénales/vascularisation , Hormone corticotrope/administration et posologie , Prélèvement d'échantillon sanguin/méthodes , Hyperaldostéronisme/sang , Glandes surrénales/effets des médicaments et des substances chimiques , Adulte , Prélèvement d'échantillon sanguin/normes , Cathétérisme/méthodes , Cathétérisme/normes , Femelle , Humains , Hyperaldostéronisme/traitement médicamenteux , Perfusions veineuses , Injections veineuses , Mâle , Adulte d'âge moyen , Études rétrospectives
20.
N Engl J Med ; 385(22): 2059-2065, 2021 11 25.
Article de Anglais | MEDLINE | ID: mdl-34818480

RÉSUMÉ

The integration of genomic testing into clinical care enables the use of individualized approaches to the management of rare diseases. We describe the use of belzutifan, a potent and selective small-molecule inhibitor of the protein hypoxia-inducible factor 2α (HIF2α), in a patient with polycythemia and multiple paragangliomas (the Pacak-Zhuang syndrome). The syndrome was caused in this patient by somatic mosaicism for an activating mutation in EPAS1. Treatment with belzutifan led to a rapid and sustained tumor response along with resolution of hypertension, headaches, and long-standing polycythemia. This case shows the application of a targeted therapy for the treatment of a patient with a rare tumor-predisposition syndrome. (Funded by the Morin Family Fund for Pediatric Cancer and Alex's Lemonade Stand Foundation.).


Sujet(s)
Tumeurs de la surrénale/traitement médicamenteux , Facteurs de transcription à motif basique hélice-boucle-hélice/antagonistes et inhibiteurs , Indènes/usage thérapeutique , Paragangliome/traitement médicamenteux , Polyglobulie/traitement médicamenteux , Adolescent , Tumeurs de la surrénale/génétique , Glandes surrénales/imagerie diagnostique , Glandes surrénales/effets des médicaments et des substances chimiques , Glandes surrénales/anatomopathologie , Facteurs de transcription à motif basique hélice-boucle-hélice/génétique , Marqueurs biologiques/sang , Chromogranine/sang , Femelle , Mutation gain de fonction , Humains , Indènes/effets indésirables , Imagerie par résonance magnétique , Normétanéphrine/sang , Paragangliome/génétique , Polyglobulie/génétique , Transduction du signal , Syndrome , Séquençage du génome entier
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE